Navigation Links
The fight against uterine fibroid tumors
Date:4/27/2010

CHICAGO ---As many as 75 percent of women have uterine fibroids (leiomyomas), and approximately one-third to one-half of those women become symptomatic at some point during their reproductive lives experiencing irregular uterine bleeding, anemia, pelvic pain or recurrent pregnancy loss.

"Uterine fibroids represent the most prevalent benign gynecologic problem in our nation. This is truly an understudied area and a serious public health problem," said Serdar E. Bulun, M.D., George H. Gardner professor of clinical gynecology and chief of the division of reproductive biology research at Northwestern University Feinberg School of Medicine, who also is a physician at Northwestern Memorial Hospital.

Thanks to $5.7 million in funding from the Eunice Kennedy Shriver National Institute of Child Health and Development, part of the National Institutes of Health, Bulun and researchers at the Uterine Leiomyoma Research Center at Feinberg have the funding they need to continue investigating new treatments of uterine fibroids.

Principal investigator of the center grant, Bulun is studying the cause of this chronic problem, as well as treatment options such as investigating hormonal pathways and defining molecular targets for existing or upcoming pharmaceutical compounds developing novel and alternative management options.

Bulun's research suggests that the hormone progesterone, which enables and activates fibroid growth during childbearing years, stimulates uterine fibroids. His recent work uncovered the mechanism as to how a class of drugs called selective progesterone receptor modulators reduces fibroid size and associated symptoms. The mechanisms regulating the development and growth of these tumors are still not well understood, however, so treatment options for fibroids are limited.

Besides Bulun, Julie Kim, Debu Chakravarti, Takeshi Kurita, and Erica Marsh, M.D., from Feinberg and Romana Nowak, from University of Illinois at Urbana-Champaign, lead key projects at the Uterine Leiomyoma Research Center.

Uterine fibroids are typically treated surgically, through a myomectomy or hysterectomy, or using newer technologies involving interventional radiology or high-intensity ultrasound. GnRH agonists, developed in the 1980s, are the only class of drugs available to treat fibroids, but their success is extremely limited, and side effects prevent long-term use of the medication.

The renewable five-year P01 Program Project offers Bulun and his colleagues the opportunity to find answers to these uncertainties and diminish the suffering caused by uterine fibroids.

"This center is a unique entity," Bulun said. "We approach the translational aspects of uterine fibroids in a multidisciplinary manner. We hope our research will encourage the pharmaceutical industry and clinicians to set up clinical trials."


'/>"/>

Contact: Erin White
ewhite@northwestern.edu
847-491-4888
Northwestern University
Source:Eurekalert

Related biology news :

1. Clemson chemists discover new way antioxidants fight debilitating diseases
2. Social habits of cells may hold key to fighting diseases
3. Advance in effort to fight malaria by tricking the mosquitos sense of smell
4. Yale scientists use nanotechnology to fight E. coli
5. Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
6. Japanese beetle may help fight hemlock-killing insect
7. When it comes fighting to C. difficile, the Palme dOr goes to soap and warm water
8. Fighting the spread of food poisoning
9. Gold nanorods shed light on new approach to fighting cancer
10. UMass Medical School researchers receive $8.5M grant award to fight AIDS
11. UV light improving chances of fighting cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 21, 2017 Optimove ... used by retailers such as 1-800-Flowers and AdoreMe, ... — Product Recommendations and Replenishment. Using Optimove,s machine learning ... personalized product and replenishment recommendations to their customers ... on predictions of customer intent drawn from a ...
(Date:3/13/2017)... -- Future of security: Biometric Face Matching software  ... ... Face Matching enables to match face pictures against each other or against large ... Identification Systems) ... is the fastest software for biometric Face Matching on the market. The speed ...
(Date:3/6/2017)... MATEO, Calif. , March 6, 2017 /PRNewswire/ ... marketing and sales technology, today announced Predictive Sales ... solution for infusing actionable sales intelligence into Salesforce. ... to automatically enable their sales organizations with deep ... messages that allow for intelligent engagement. Predictive Sales ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... ... March 28, 2017 , ... ... release of LabKey’s newest software solution, LabKey Biologics . Built in collaboration ... and biotech organizations, LabKey Biologics provides drug research teams tools for biological entity ...
(Date:3/28/2017)... 28, 2017 Focus is ... sector due to the scientifically intensive operations of ... agricultural, environmental, and industrial. In today,s pre-market research, Stock-Callers.com ... Inc. (NASDAQ: PTLA), OvaScience Inc. (NASDAQ: OVAS), Ocera ... (NASDAQ: OCUL ). Learn more about ...
(Date:3/28/2017)... 28, 2017 /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: ... compelling safety and clinical data from its phase 1/2 tendon ... hair follicle-derived fibroblasts (RCT-01) as a treatment for Achilles tendinosis. ... ... safety profile at 6 months and showed no serious adverse ...
(Date:3/28/2017)... ... March 28, 2017 , ... Executive search firm, ... Avomeen Analytical Services. Harvill is a distinguished life sciences expert with a proven ... a leader in a wide range of services related to laboratory testing and ...
Breaking Biology Technology: